Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

Remix Therapeutics will replace Passage Bio on the Nasdaq in an all-stock reverse merger, with the combined company trading under the ticker RMTX.

Remix, a clinical-stage RNA-targeting biotech, will operate under its own name and host its pipeline of small molecule mRNA degraders, including lead candidate REM-422.

Passage Bio shareholders will own about 7% of the combined company; Remix will receive roughly $100 million in a concurrent private placement, funding operations into 2028.

REM-422, an oral mRNA degrader, targets the MYB transcription factor implicated in several cancers, and is in Phase 1/2 trials for adenoid cystic carcinoma and AML/HR-MDS.

The merger is expected to close in Q4 2026, subject to shareholder and regulatory approvals, marking a strategic pivot for Passage Bio from gene therapy to an RNA-focused oncology platform.